Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production

Parag Singhal, Andrea Caumo, Claudio Cobelli, Roy Taylor

Research output: Contribution to journalArticle

Abstract

The effect of repaglinide and gliclazide on postmeal suppression of endogenous glucose production (EGP) has been studied using a variable-rate tracer methodology. Groups of age-, sex-, and weight-matched type 2 diabetic subjects randomized to gliclazide or repaglinide were studied after ingesting a standard mixed meal (550 kcal; 67% carbohydrate, 19% fat, 14% protein). Plasma glucose profiles were similar in each group and markedly different from that of a nondiabetic control group. Endogenous glucose production was similar basally (3.01 ± 0.30 vs 3.06 ± 0.19 mg/kg per minute, gliclazide and repaglinide, respectively). After glucose ingestion, EGP declined rapidly in both the groups until 30 minutes and the greatest suppression was reached earlier in the repaglinide group [0.88 mg/kg per minute at 120 minutes vs 0.77 mg/kg per minute at 210 minutes in gliclazide group (P 2; P >. 02) but not significantly different in the repaglinide group (153 ± 25 mg/kg per min 2; P =. 17). Repaglinide has minimal physiological advantage over gliclazide, but both therapies for type 2 diabetes fall far short of correcting the endocrine and metabolic abnormalities.

Original languageEnglish
Pages (from-to)79-84
Number of pages6
JournalMetabolism
Volume54
Issue number1
DOIs
Publication statusPublished - Jan 2005

Fingerprint

repaglinide
Gliclazide
Glucose
Type 2 Diabetes Mellitus
Meals
Age Groups
Eating
Fats
Carbohydrates

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production. / Singhal, Parag; Caumo, Andrea; Cobelli, Claudio; Taylor, Roy.

In: Metabolism, Vol. 54, No. 1, 01.2005, p. 79-84.

Research output: Contribution to journalArticle

Singhal, Parag ; Caumo, Andrea ; Cobelli, Claudio ; Taylor, Roy. / Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production. In: Metabolism. 2005 ; Vol. 54, No. 1. pp. 79-84.
@article{a46defabd314403981268b6cacf71fba,
title = "Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production",
abstract = "The effect of repaglinide and gliclazide on postmeal suppression of endogenous glucose production (EGP) has been studied using a variable-rate tracer methodology. Groups of age-, sex-, and weight-matched type 2 diabetic subjects randomized to gliclazide or repaglinide were studied after ingesting a standard mixed meal (550 kcal; 67{\%} carbohydrate, 19{\%} fat, 14{\%} protein). Plasma glucose profiles were similar in each group and markedly different from that of a nondiabetic control group. Endogenous glucose production was similar basally (3.01 ± 0.30 vs 3.06 ± 0.19 mg/kg per minute, gliclazide and repaglinide, respectively). After glucose ingestion, EGP declined rapidly in both the groups until 30 minutes and the greatest suppression was reached earlier in the repaglinide group [0.88 mg/kg per minute at 120 minutes vs 0.77 mg/kg per minute at 210 minutes in gliclazide group (P 2; P >. 02) but not significantly different in the repaglinide group (153 ± 25 mg/kg per min 2; P =. 17). Repaglinide has minimal physiological advantage over gliclazide, but both therapies for type 2 diabetes fall far short of correcting the endocrine and metabolic abnormalities.",
author = "Parag Singhal and Andrea Caumo and Claudio Cobelli and Roy Taylor",
year = "2005",
month = "1",
doi = "10.1016/j.metabol.2004.07.014",
language = "English",
volume = "54",
pages = "79--84",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production

AU - Singhal, Parag

AU - Caumo, Andrea

AU - Cobelli, Claudio

AU - Taylor, Roy

PY - 2005/1

Y1 - 2005/1

N2 - The effect of repaglinide and gliclazide on postmeal suppression of endogenous glucose production (EGP) has been studied using a variable-rate tracer methodology. Groups of age-, sex-, and weight-matched type 2 diabetic subjects randomized to gliclazide or repaglinide were studied after ingesting a standard mixed meal (550 kcal; 67% carbohydrate, 19% fat, 14% protein). Plasma glucose profiles were similar in each group and markedly different from that of a nondiabetic control group. Endogenous glucose production was similar basally (3.01 ± 0.30 vs 3.06 ± 0.19 mg/kg per minute, gliclazide and repaglinide, respectively). After glucose ingestion, EGP declined rapidly in both the groups until 30 minutes and the greatest suppression was reached earlier in the repaglinide group [0.88 mg/kg per minute at 120 minutes vs 0.77 mg/kg per minute at 210 minutes in gliclazide group (P 2; P >. 02) but not significantly different in the repaglinide group (153 ± 25 mg/kg per min 2; P =. 17). Repaglinide has minimal physiological advantage over gliclazide, but both therapies for type 2 diabetes fall far short of correcting the endocrine and metabolic abnormalities.

AB - The effect of repaglinide and gliclazide on postmeal suppression of endogenous glucose production (EGP) has been studied using a variable-rate tracer methodology. Groups of age-, sex-, and weight-matched type 2 diabetic subjects randomized to gliclazide or repaglinide were studied after ingesting a standard mixed meal (550 kcal; 67% carbohydrate, 19% fat, 14% protein). Plasma glucose profiles were similar in each group and markedly different from that of a nondiabetic control group. Endogenous glucose production was similar basally (3.01 ± 0.30 vs 3.06 ± 0.19 mg/kg per minute, gliclazide and repaglinide, respectively). After glucose ingestion, EGP declined rapidly in both the groups until 30 minutes and the greatest suppression was reached earlier in the repaglinide group [0.88 mg/kg per minute at 120 minutes vs 0.77 mg/kg per minute at 210 minutes in gliclazide group (P 2; P >. 02) but not significantly different in the repaglinide group (153 ± 25 mg/kg per min 2; P =. 17). Repaglinide has minimal physiological advantage over gliclazide, but both therapies for type 2 diabetes fall far short of correcting the endocrine and metabolic abnormalities.

UR - http://www.scopus.com/inward/record.url?scp=9644284519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9644284519&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2004.07.014

DO - 10.1016/j.metabol.2004.07.014

M3 - Article

C2 - 15562384

AN - SCOPUS:9644284519

VL - 54

SP - 79

EP - 84

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 1

ER -